Head To Head Top Stocks: trivago N.V. (NASDAQ:TRVG), Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

trivago N.V. (NASDAQ:TRVG)

trivago N.V. (NASDAQ:TRVG) closed at $4.47 on the last trading session with an decrease of -0.89%, whereas, it previously closed at $4.51. The company has a market capitalization of $1.61 Billion. The company traded shares of 261994 on the trading day while its three month average volume stands at 360.53 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of trivago N.V. (NASDAQ:TRVG) produced diluted EPS of 0.11. The EPS estimate for next year as estimated by analysts is at 0.11 while EPS for next quarter is estimated at 0.02. Earnings per Share growth for this year is reported at -34.8, while the analysts estimated the EPS growth for next year at 0.11% and Earnings growth for next 5 years stands at 34.84% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 0%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of trivago N.V. (NASDAQ:TRVG) is at 41.01 while the forward p/e is at 39.56. The P/S or Price to Sales ratio of trivago N.V. (NASDAQ:TRVG) stands at 1.71 and Price to Book or P/B for the most recent quarter stands at 1.61. The Price to Free Cash Flow ratio or P/FCF is reported at 12.75. The quick ratio and the current ratio of trivago N.V. (NASDAQ:TRVG) are reported at 3.3 and 3.3 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for trivago N.V. (NASDAQ:TRVG) stands at 3.1, 4 and -2.1 respectively

The trailing twelve month Revenue of trivago N.V. (NASDAQ:TRVG) is reported at 943.1 Million with income of 38.5 Million. The outstanding shares of trivago N.V. (NASDAQ:TRVG) are 360.97 Million. The institutional Ownership of the shares of 96.2 stands at 0.80%, this figure is increased 1.81 in the last six months. The insider ownership for the shares of trivago N.V. (NASDAQ:TRVG) is ticked at 4.98%, the figure is rose 0% in the last six months.

Some other important financial aspects to be discussed here for trivago N.V. (NASDAQ:TRVG) is the Mean Target Price estimated by the analysts which stands at 5.13. The 52 week high of trivago N.V. (NASDAQ:TRVG) is placed at 7.54 and 52 week low is standing at 3.41.

Performance wise the shares of trivago N.V. (NASDAQ:TRVG) fell down -0.89% for the week, it also fell -5.1% for the monthly performance, while for the quarter it went down 15.21%. The shares decrease -4.89% for the half year and plummeted for the Year-To-Date performance. The shares of trivago N.V. (NASDAQ:TRVG) shrinked -8.21% for the yearly performance.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) closed at $1.57 on the last trading session with an decrease of -9.77%, whereas, it previously closed at $1.74. The company has a market capitalization of $82.58 Million. The company traded shares of 1.35 Million on the trading day while its three month average volume stands at 1.2 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) produced diluted EPS of -0.99. The EPS estimate for next year as estimated by analysts is at -0.8 while EPS for next quarter is estimated at -0.23. Earnings per Share growth for this year is reported at -11.9, while the analysts estimated the EPS growth for next year at -0.8% and Earnings growth for next 5 years stands at 0% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at -3.9%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is at 0 while the forward p/e is at 0. The P/S or Price to Sales ratio of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) stands at 0 and Price to Book or P/B for the most recent quarter stands at 1.76. The Price to Free Cash Flow ratio or P/FCF is reported at 0. The quick ratio and the current ratio of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) are reported at 5.9 and 5.9 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) stands at -75.6, -88.8 and 0 respectively

The trailing twelve month Revenue of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is reported at 0 with income of -46100000. The outstanding shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) are 52.6 Million. The institutional Ownership of the shares of 72.4 stands at 0.80%, this figure is increased 3.06 in the last six months. The insider ownership for the shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is ticked at 0.6%, the figure is plummeted -7.12% in the last six months.

Some other important financial aspects to be discussed here for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is the Mean Target Price estimated by the analysts which stands at 6.88. The 52 week high of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is placed at 10.54 and 52 week low is standing at 0.77.

Performance wise the shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) fell down -12.78% for the week, it also rise 40.18% for the monthly performance, while for the quarter it went up -61.71%. The shares decrease -59.85% for the half year and plummeted for the Year-To-Date performance. The shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) shrinked -77.57% for the yearly performance.